Estimating costs of adverse events (AEs) and healthcare resource use (HRU) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) receiving tisagenlecleucel (tisa-cel) and axicabtagene ciloleucel (axi-cel): A summary of real-world evidence.

被引：0
|
作者：
Yang, Hongbo
Qi, Cynthia Zhengyun
Dalal, Anand
Bollu, Vamsi
Zhang, Jie
Zhang, Su
Lim, Stephen
机构：
[1] Anal Grp Inc, Boston, MA USA
[2] Novartis Pharmaceut Corp, E Hanover, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e19551
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19551
引用
收藏
页数：3
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF AXICABTAGENE CILOLEUCEL (AXI-CEL) AND TISAGENLECLEUCEL (TISA-CEL) IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL) IN CANADA
    Ball, G.
    Kuruvilla, J.
    Boodoo, C.
    Jain, M. D.
    VALUE IN HEALTH, 2021, 24 : S39 - S39
  • [2] INDIRECT TREATMENT COMPARISON OF AXICABTAGENE CILOLEUCEL (AXI-CEL) VERSUS TISAGENLECLEUCEL (TISA-CEL) IN RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA (RR-LBCL)
    Oluwole, O.
    Jansen, J. P.
    Lin, V
    Chan, K.
    Navale, L.
    Kim, J. J.
    Locke, F. L.
    VALUE IN HEALTH, 2019, 22 : S522 - S522
  • [3] Single-Center Experience with Axicabtagene-Ciloleucel (Axi-cel) and Tisagenlecleucel (Tisa-cel) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Comparable Response Rates and Manageable Toxicity
    Buecklein, Veit
    Blumenberg, Viktoria
    Ackermann, Josephine
    Schmidt, Christian
    Rejeski, Kai
    Mueller, Niklas
    Reischer, Anna
    von Baumgarten, Louisa
    Schoeberl, Florian
    Humpe, Andreas
    von Bergwelt, Michael
    Subklewe, Marion
    BLOOD, 2020, 136
  • [4] Evaluation of Outcomes and Toxicities of Commercial Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Real-World Evidence (RWE) from 10 US Academic Centers
    Sharp, John
    Strati, Paolo
    Bhatta, Subodh
    Huang, Jennifer J.
    Thomas, Colin
    Reef, Daniel K.
    Gorzewski, Alexander
    Reinert, Catherine
    Teferra, Andinet
    Pelcovits, Ari
    Ollila, Thomas
    Maakaron, Joseph E.
    Kamdar, Manali K.
    Fitzgerald, Lindsey
    Karmali, Reem
    Grover, Natalie
    Barta, Stefan K.
    Voorhees, Timothy
    Shadman, Mazyar
    Ahmed, Sairah
    Epperla, Narendranath
    BLOOD, 2024, 144 : 2377 - 2378
  • [5] Comparative efficacy of tisagenlecleucel (tisa-cel) and lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL).
    Schuster, Stephen J.
    Zhang, Jie
    Yang, Hongbo
    Agarwal, Abhijit
    Tang, Wenxi
    Martinez-Prieto, Marcela
    Bollu, Vamsi
    Ma, Qiufei
    Kuzan, David
    Maziarz, Richard T.
    Kersten, Marie Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL)
    Topp, Max S.
    van Meerten, Tom
    Houot, Roch
    Minnema, Monique
    Milpied, Noel
    Lugtenburg, Pieternella J.
    Thieblemont, Catherine
    Wermke, Martin
    Song, Kevin
    Avivi, Irit
    Kuruvilla, John
    Duehrsen, Ulrich
    Chu, Rachel
    Zheng, Lianqing
    Plaks, Vicki
    Kerber, Anne
    Kersten, Marie Jose
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S101 - S101
  • [7] Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Real-World Practice Patterns and Outcomes
    Khurana, Arushi
    Bailey, Megumi
    Iqbal, Madiha
    Bansal, Radhika
    Lee, Catherine J.
    Hunter, Bradley
    Lunning, Matthew A.
    Jaglowski, Samantha
    Jain, Michael D.
    Dahiya, Saurabh
    Bachanova, Veronika
    Farooq, Umar
    Ahmed, Sairah
    Hill, Brian T.
    Munoz, Javier L.
    Patel, Krish
    Oluwole, Olalekan O.
    Lin, Yi
    BLOOD, 2022, 140 : 4657 - 4660
  • [8] Earlier Steroid Use With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 12 - 14
  • [9] Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL)
    Topp, Max S.
    van Meerten, Tom
    Hout, Roch
    Minnema, Monique C.
    Milpied, Noel
    Lugtenburg, Pieternella J.
    Thieblemont, Catherine
    Wermke, Martin
    Song, Kevin W.
    Avivi, Irit
    Kuruvilla, John
    Duehrsen, Ulrich
    Chu, Rong
    Zheng, Lianqing
    Plaks, Vicki
    Kerber, Anne
    Kersten, Marie Jose
    MOLECULAR THERAPY, 2020, 28 (04) : 577 - 577
  • [10] Preliminary results of earlier steroid use with axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).
    Topp, Max S.
    van Meerten, Tom
    Wermke, Martin
    Lugtenburg, Elly J.
    Minnema, Monique C.
    Song, Kevin W.
    Thieblemont, Catherine
    Jiang, Yizhou
    Plaks, Vicki
    Kerber, Anne
    Kersten, Marie Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345